NTCELL

ASX
LCT 0.041   Last updated EOD 10th December 2018
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

Product profile

NTCELL® is expected to be indicated for restoration of function and slowing of disease progression in younger patients with early stage Parkinson’s disease experiencing reduced response to standard medical therapy – any one of the following:
                                -  "On" time characterised by dyskinesias (or other non-motor side effects)
                                -  "Off" time characterised by tremor, rigidity, or akinesia/bradykinesia.
                                -  "On/Off" motor fluctuations. 

PRINT PAGE print-icon
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.